News & Updates

2026-08-17

YuGen Pharmaceutical's Second-Generation Probiotic Research Progress: Three AKK2645 Studies Published in International Journals

2026-08-03

Sungen Biomedical's SGC001 Approved for Clinical Trial of New Indication: Predicted Severe Acute Pancreatitis

2026-07-27

Youngen Biotechnology: Hotgen Biotech Establishes an AI Pharmaceutical Company to Focus on Small Nucleic Acid Drug R&D

2026-07-27

Major Innovative Drug Program: Sungen Biomedical's SGC001 Project Approved for the 2026 National Science and Technology Major Project for Innovative Drug R&D

2026-07-27

Good News! The Key Laboratory for Cardiovascular Antibody and Macromolecular Innovative Drugs Led by Hotgen Biotech Has Been Officially Approved

2026-07-27

NMPA IND Submission! Sungen Biomedical's New SGC001 Indication, Predicted Severe Acute Pancreatitis, Officially Enters a New Stage of Clinical Development

2026-07-27

Innovative Drug Update: Kick-off Meeting for the National Science and Technology Major Project Development of a Novel Biological Drug for the Treatment of Alzheimer's Disease Successfully Held

2026-07-27

Hotgen Biotech Reaches Strategic Cooperation with JOINN Biologics and JOINN Laboratories to Build a Full-Chain Innovative Drug R&D Service System

2026-07-27

Four Small Nucleic Acid Patents! Keygen Biomed's Invention Patents for a Series of Small Nucleic Acid Drugs for Metabolic Diseases Were Published Together

2026-07-27

Chuangjing Update | iRegene Therapeutics' Parkinson's Disease Cell Therapy Product Completes China Phase II Enrollment and Dosing Plan, Competing Internationally Through Core Platform Strength